

In the matter of the Canadian Anti-Doping Program;

And in the matter of an anti-doping rule violation by Cody Hudson asserted by the Canadian Centre for Ethics in Sport;

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on January 10, 2025, in Calgary, AB.¹
2. Cody Hudson (“the Athlete”) was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (AAF) for Amphetamine, a non-Specified Substance, and Cannabis: Carboxy-THC (“Cannabis”), a Specified Substance, both included on the World Anti-Doping Agency’s (WADA) 2025 Prohibited List.
3. The Athlete was granted a retroactive Therapeutic Use Exemption (TUE) for his anti-doping rule violation (ADRV) involving Amphetamine.
4. Following receipt of the CCES’s Notice of Charge letter asserting an ADRV for the presence and Use of Cannabis, the Athlete admitted the violation, waived his right to a hearing, and agreed to a three (3) month period of Ineligibility and all applicable Consequences by signing an Agreement on Consequences.

Jurisdiction

5. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada and is responsible for handling the administration of the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
6. As Canada’s National Anti-Doping Organization, the CCES is compliant the World Anti-Doping Code (“the Code”) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
7. The Athlete is a member of and participates in the activities of Volleyball Canada. According to CADP Rule 1.3, the CADP provisions apply to all members of and Participants in activities of adopting Sport Organizations. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. Volleyball Canada adopted the CADP on December 16, 2020. Therefore, the Athlete is subject to the CADP.

¹ The Athlete was tested due to their participation in a U SPORTS volleyball competition; however, the Athlete is also included in Volleyball Canada’s National Athlete Pool (NAP) and does not meet the CADP definition of “Student-Athlete.” The Athlete is therefore ineligible for the medical review process described in CADP Rule 4.5.

Doping Control

8. On January 10, 2025, the CCES conducted an In-Competition Sample collection session in Calgary, AB. Testing was conducted as part of the CCES's domestic test distribution plan under the CADP.
9. The Athlete was notified that he had been selected for Doping Control and, together with the Doping Control Officer from the CCES, completed the Sample collection process. The Athlete's Sample code number was 8073985.

Results Management

10. On January 15, 2025, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS") in Laval, QC, a WADA-accredited laboratory.
11. The AAF was reported by the INRS on February 4, 2025. The Certificate of Analysis indicated the presence of Amfetamine and Cannabis.
12. Amfetamine is classified as a non-Specified Substance and Cannabis as a Specified Substance on WADA's 2025 Prohibited List. Both substances are prohibited In-Competition only.
13. On February 25, 2025, the CCES issued to the Athlete a Notification of a potential ADRV for the presence and Use of Prohibited Substances.
14. Between March 4 and March 25, 2025, the Athlete provided his explanations.
15. On March 25, 2025, the Athlete accepted a voluntary Provisional Suspension.
16. On April 16, 2025, a Therapeutic Use Exemption (TUE) was granted to the Athlete for their Use of Amfetamine, retroactively effective from the date of Sample Collection (January 10, 2025). Consequently, no ADRV was pursued for this AAF.
17. On June 19, 2025, the CCES formally issued a Notice of Charge and Agreement on Consequences, asserting an ADRV against the Athlete for the presence and Use of Cannabis.
18. After assessing all the information provided by the Athlete, the CCES asserted a three (3) month period of Ineligibility to the Athlete in accordance with CADP Rule 10.2.4.1. Further, the CCES indicated that the asserted three (3) month period of Ineligibility could be reduced to one (1) month if the Athlete completed a Substance of Abuse treatment program approved by the CCES

Confirmation of Violation and Sanction

19. On July 2, 2025 an Agreement on Consequences was entered into between the Athlete and the CCES, pursuant to which an ADRV was confirmed against the Athlete for the presence and Use of Cannabis. In accordance with CADP Rule 10.2.4.1, the sanction for this violation is a three (3) month period of Ineligibility that came into effect on March 25, 2025 (the date

the Athlete accepted a Provisional Suspension) and remained in force and effect until June 24, 2025.

20. Further, Pursuant to CADP Rules 9, 10.1 and 10.10, all competitive results of the Athlete obtained after the date of commission of the ADRV (January 10, 2025) until the date the Athlete accepted a Provisional Suspension shall be Disqualified, including the forfeiture of any medals, points and prizes.

21. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 10th day of July 2025.



Kevin Bean
Executive Director, Sport Integrity
CCES